The buzz around a potential acquisition by Gilead continues. Last week a new name entered the ring - Vertex Pharmaceuticals. Leerink's Geoffrey Porges suggested this possibility. The scale of such an acquisition would likely meet expectations of many analysts even though Vertex would be a deviation from the anticipated play in oncology.
More information here:
https://endpts.com/gilead-buy-vertex-a-golden-oldie-in-the-ma-buzz-circuit-gets-fresh-air-time